Semaglutide Improved Memory and Muscle in Old Mice and Extended Their Lifespan

Semaglutide improved memory, muscle function and blood sugar control in ageing mice, and extended their lifespan by more than calorie restriction did in the same experiments. The finding puts a widely prescribed drug into a field that has so far produced very little that translates.

What the experiment compared

The comparison is what makes the result notable. Calorie restriction is the oldest and most reproducible intervention in ageing research -- reduce food intake substantially without malnutrition and animals across many species live longer. It is also close to unusable in people, because few can sustain it and the trade-offs in muscle mass and bone are real. A drug that matched or exceeded it would be a considerable finding.

In these experiments, treated animals performed better on memory tasks, retained more muscle function, maintained better glucose control, and lived longer than both untreated controls and calorie-restricted animals.

Why it is biologically plausible

Ageing and metabolic dysfunction are entangled. Insulin resistance, chronic low-grade inflammation and impaired cellular clearance all increase with age and all contribute to age-related disease. GLP-1 receptor agonists act on several of these, and receptors for GLP-1 are present in the brain as well as in the pancreas and gut -- which is the starting point for the interest in cognitive effects.

The reasons for caution are substantial

Mouse lifespan studies have a poor translation record. Laboratory mice are genetically uniform, kept in clean conditions, fed a standard diet, and typically die of a narrow range of causes; none of that resembles human ageing. Many interventions that extended mouse lifespan have done nothing measurable in people.

There is also a specific concern for older adults. A significant fraction of the weight lost on GLP-1 drugs is lean mass, and in a population already losing muscle with age, that is not a neutral cost. Frailty and falls are among the things that most determine independence after 70.

What would be needed

Trials in older adults with function as the endpoint -- muscle strength, cognition, independence -- rather than weight. Some are under way for cardiovascular and cognitive outcomes; none is designed as a longevity trial, and none will report soon.

Bottom line

Nobody should be seeking a GLP-1 prescription to slow ageing. For people who have one for diabetes or obesity, this is a reason for interest, not for a change of plan.